Results 11 to 20 of about 4,707 (174)

Sex Differences in Outcomes After Tenecteplase for Minor Stroke: A Subanalysis of the TEMPO‐2 Trial [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In this subanalysis of the TEMPO‐2 (Tenecteplase Versus Standard of Care for Minor Ischaemic Stroke With Proven Occlusion) trial, a randomized clinical trial comparing tenecteplase and nonthrombolytic control in patients with minor stroke and ...
Amy Y. X. Yu, Shabnam Vatanpour, Aravind Ganesh, Thalia S. Field, Philip A. Barber, Philip M. C. Choi, Brian Buck, Timothy Kleinig, Carlos A. Molina, Bruce C. V. Campbell, Ramana Appireddy, Keith W. Muir, Michael D. Hill, Shelagh B. Coutts   +13 more
doaj   +7 more sources

Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review

International Journal of Emergency Medicine, 2022
Introduction Thrombolysis for acute ischemic stroke (AIS) with alteplase is the currently approved therapy for patients who present within 4.5 h of symptom onset and meet criteria.
Neha Potla, Latha Ganti
doaj   +2 more sources

Tenecteplase Improves Door‐to‐Needle Time in Real‐World Acute Stroke Treatment

Stroke: Vascular and Interventional Neurology, 2021
Background We report the interim results of a process improvement initiative at a comprehensive stroke center in which all tPA (tissue‐type plasminogen activator)–eligible patients were given tenecteplase for acute ischemic stroke.
Jillian Hall, Jesse M. Thon, Mark Heslin, Lauren Thau, Terri Yeager, Taylor Siegal, Nicholas Vigilante, Scott Kamen, Justin Tiongson, Tudor G. Jovin, James E. Siegler   +10 more
doaj   +2 more sources

Tenecteplase Versus Alteplase in Medium Vessel Occlusion Ischemic Stroke: A Secondary Analysis of the Alteplase Compared to Tenecteplase Randomized Trial [PDF]

Journal of Stroke
Background and Purpose The safety and efficacy of tenecteplase in patients with ischemic stroke due to medium vessel occlusion (MeVO) are not well studied. We aimed to compare tenecteplase with alteplase in stroke due to MeVO.
Fouzi Bala, Nishita Singh, Katrina Ignacio, Ibrahim Alhabli, Ayoola Ademola, Anas Alrohimi, Houman Khosravani, Aleksander Tkach, Luciana Catanese, Dariush Dowlatshahi, Thalia Field, Gary Hunter, Faysal Benali, MacKenzie Horn, Andrew Demchuk, Michael Hill, Tolulope Sajobi, Brian Buck, Richard Swartz, Mohammed Almekhlafi, Bijoy K. Menon   +20 more
doaj   +3 more sources

Bibliometric analysis of the usage of tenecteplase for stroke

International Journal of Emergency Medicine
Introduction In recent years, tenecteplase has been competing with alteplase as a treatment for acute ischemic stroke given its ease of administration, lower dosage, cost-effectiveness, and better safety data.
Garv Bhasin, Latha Ganti
doaj   +2 more sources

Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials

Drug Design, Development and Therapy, 2018
Na Xu,1,2,* Zhouqing Chen,1,* Chongshun Zhao,1 Tao Xue,1 Xin Wu,1 Xiaoou Sun,1 Zhong Wang1 1Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ...
Xu N, Chen Z, Zhao C, Xue T, Wu X, Sun X, Wang Z   +6 more
doaj   +1 more source

Tenecteplase: biochemical and clot lysis activity comparisons [PDF]

Frontiers in Pharmacology
IntroductionIn the last decades, the recombinant tissue plasminogen activator alteplase has been the standard fibrinolytic treatment of acute myocardial infarction, pulmonary embolism, and acute ischemic stroke.
Jan Bechmann, Ira Schmid, Simone Brand, Felix Miller, Chengzhi Zhang   +4 more
doaj   +2 more sources

Enhancement of Tenecteplase Thrombolytic Actions Ex Vivo and In Vivo by Deoxyribonuclease I

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background We aimed to investigate the phenomenon of thrombolysis resistance in tenecteplase and its underlying causes and evaluate whether DNase‐1 (deoxyribonuclease I) targeting neutrophil extracellular traps (NETs) could enhance the thrombolytic ...
Shuhan Xu, Zhiyong Yang, Jinyu Jia, Shijun Zhang, Shengming Huang, Liang Zhang, Min Guan, Guobing Chen, Xinyi Leng, Li’an Huang   +9 more
doaj   +2 more sources

Tenecteplase compared to alteplase in real-world outcome: A Swedish Stroke Register study

Upsala Journal of Medical Sciences
Background: Tenecteplase is increasingly used off-label as an alternative to alteplase for ischemic stroke thrombolysis. Our aim was to evaluate the safety of tenecteplase versus alteplase in comprehensive real-world data.
Mikael Skärlund, Signild Åsberg, Marie Eriksson, Erik Lundström   +3 more
doaj   +2 more sources

Tenecteplase Thrombolysis in Posterior Circulation Stroke [PDF]

, 2021
One in five ischaemic strokes affects the posterior circulation. Basilar artery occlusion is a type of posterior circulation stroke associated with a high risk of disability and mortality.
Campbell, BCV, Alemseged, F, Fana Alemseged, Bruce C. V. Campbell   +3 more
core   +1 more source